联系客服

600479 沪市 千金药业


首页 公告 千金药业:千金药业2023年三季度主要经营数据公告

千金药业:千金药业2023年三季度主要经营数据公告

公告日期:2023-10-28

千金药业:千金药业2023年三季度主要经营数据公告 PDF查看PDF原文

  证券代码:600479      证券简称:千金药业        公告编号:2023-054
            株洲千金药业股份有限公司

          2023 年三季度主要经营数据公告

  本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。

  根据《上市公司行业信息披露指引第六号——医药制造(2022年修订)》及《关于做好主板上市公司 2023 年第三季度报告披露工作的重要提醒》的要求,公司现将 2023 年第三季度主要经营数据披露如下:

  一、报告期内公司主营业务分行业经营情况

                                      单位:元 币种:人民币

                                                营业  营业

                                                收入  成本  毛利率
                                        毛利  比上  比上  比上年
 分行业    营业收入      营业成本      率  年同  年同  同期增
                                        (%)  期增  期增  减(%)
                                                减    减

                                              (%)  (%)

 药品生                                                                减少

  产    1,346,318,524.41  423,049,877.13  68.58  1.54    8.13  1.91 个
                                                                      百分点

 中药材                                                                减少

 及饮片    83,319,342.40    59,526,898.62  28.56  163.24  166.26  0.81 个
  生产                                                                百分点

 药品批                                                                增加

 发零售  1,234,322,848.91  1,010,683,684.42  18.12  -13.74  -16.57  2.78 个
                                                                      百分点

                                                                        增加

  其他    122,598,855.30    46,799,876.33  61.83  -4.55  -7.80  1.34 个
                                                                      百分点

 合并抵  -64,132,866.65    -65,101,564.80

  销


                                                                      增加
 合计  2,722,426,704.37  1,474,958,771.70  45.82  -4.18  -7.76  2.10 个
                                                                      百分点

  二、报告期内公司主营业务分产品经营情况

                                    单位:元 币种:人民币

                                              营业  营业

                                      毛利  收入  成本  毛利率
 分产                                  率    比上  比上  比上年
 品      营业收入      营业成本    (%  年同  年同  同期增
                                        )    期增  期增  减(%)
                                              减    减

                                              (%)  (%)

中药生  734,251,336.87    231,112,348.69  68.52  -6.13  4.66  减少 3.25
 产                                                                个百分点

西药生  612,067,187.54    191,937,528.44  68.64  12.59  12.62  减少 0.01
 产                                                                个百分点

中药材                                                      166.2  减少 0.81
及饮片  83,319,342.40    59,526,898.62  28.56  163.24    6    个百分点
 生产

药品批  1,234,322,848.91  1,010,683,684.42  18.12  -13.74    -    增加 2.78
发零售                                                      16.57  个百分点

 娱乐    33,022,263.31    13,015,909.34  60.58  78.24  82.00  减少 0.81
                                                                    个百分点

卫生用  85,209,877.08    31,439,559.14  63.10  -20.95    -    增加 2.68
 品                                                        26.31  个百分点

 其他    4,366,714.91      2,344,407.85    46.31  105.74  148.6  减少 9.27
                                                              9    个百分点

合并抵  -64,132,866.65    -65,101,564.80

 消

 合计  2,722,426,704.37  1,474,958,771.70  45.82  -4.18  -7.76  增加 2.10
                                                                    个百分点

  三、报告期内公司主营业务分地区经营情况

                                    单位:元 币种:人民币

  地区      2023 年 1-9 月累计主营业务收入  营业收入比上年同期增减
                                                    (%)

  华东            333,122,572.60                  -1.77

  华南            198,444,092.45                  -4.70


    华北            125,401,313.64                  -3.64

    华中            1,642,686,118.94                -1.28

    东北              62,909,541.96                  3.18

    西南            228,181,047.18                -31.14

    西北            131,682,017.60                  22.74

    合计            2,722,426,704.37                -4.18

说明:

  (1)报告期内,中药材及饮片营业收入较上年同期增长163.24%,营业成本较上年同期增长 166.26%,主要是因中药材销售同比增长所致。

  (2)娱乐营业收入较上年同期增长 78.24%,营业成本较上年同期增长 82%,主要是因电影市场回暖及增开影院所致。

  上述的主要经营数据信息来源于公司报告期内财务数据,且未经审计,敬请广大投资者审慎使用,注意风险。

  特此公告。

                                  株洲千金药业股份有限公司
                                          董事会

                                      2023 年 10 月 28 日

[点击查看PDF原文]